Dapagliflozin in Allo-HCT for aGVHD

Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Prospective, Single-Arm Study

The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.

Inclusion Criteria:

• Age 18 to 65 years old.
• Patients with hematologic malignancies indicated for allo-HCT and having a suitable haploidentical or unrelated donor.
• Willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis base on cyclosporin A and methotrexate.
• With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
• Patients with prior use of Dapagliflozin or other hypoglycemic medications may switch to Dapagliflozin, contingent upon the treating physician's assessment of contraindications, will be eligible.
• Signing an informed consent form, having the ability to comply with study and follow-up procedures.

Exclusion Criteria:

• With other malignancies.
• With a previous history of autologous hematopoietic cell transplantation, allo-HCT or chimeric antigen receptor T-cell therapy.
• With a history of allergies to Dapagliflozin.
• With type 1 diabetes or a history of ketoacidosis.
• With a history of recurrent urinary tract infections.
• With severe organ dysfunction.
• With active hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection.
• In pregnancy or lactation period.
• With any conditions not suitable for the trial (investigators' decision).